Cover Image
市場調查報告書

Erbitux(大腸癌症):市場預測與分析

Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 321683
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
Erbitux(大腸癌症):市場預測與分析 Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年11月28日 內容資訊: 英文 56 Pages
簡介

2004年2月Eli Lilly/BMS/Merck KGaA三家所開發的Erbitux(Cetuximab)是第一個通過美國FDA(食品藥物管理局)認證,針對轉移性CRC(大腸癌)之單株抗體。基因改造型·嵌合式IgG1單株抗體是以EGFR途徑為標的的新class抗體的第一個藥品。大腸癌因外皮成長因子受體(EGFR,HER1,c-ErbB-1)過剩發現頻發,因此讓細胞週期·有絲分裂的促進遺傳基因活性化。藉由Erbitux和EGFR的結合,可阻礙受體下游的信號傳送,抑制腸瘤的進行,並停止細胞周期。

本報告提供大腸癌症的治療藥之一──Erbitux(Cetuximab)的全球市場相關分析,提供大腸癌症概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Erbitux的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關的報告
  • 預定出版的相關調查報告

第3章 疾病概要

  • 病因與病情生理
    • 病因
    • 病理生理學
  • 臨床階段
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 篩檢及診斷
    • 治療的指南及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Erbitux (Cetuximab)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄
Product Code: GDHC470DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

In February 2004, Eli Lilly/BMS/Merck KGaA's Erbitux (cetuximab) became the first monoclonal antibody to be approved by the FDA for metastatic CRC. The recombinant chimeric IgG1 monoclonal antibody was the first of a novel class of antibodies that target the EGFR pathway. Overexpression of the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is frequent in CRC, where it contributes to activate genes that drive the cell cycle and mitosis. The binding of Erbitux to EGFR inhibits the downstream signaling of the receptor and hence reduces tumor progression and initiates cell cycle arrest.

Scope

  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Erbitux including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Erbitux for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Erbitux performance
  • Obtain sales forecast for Erbitux from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Erbitux (Cetuximab)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Colorectal Cancer Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Average Body Weight and Surface Area Across the 8MM
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Treatment Guidelines for CRC
  • Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
  • Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
  • Table 6: Leading Treatments for CRC, 2014
  • Table 7: Product Profile - Erbitux
  • Table 8: Erbitux SWOT Analysis, 2014
  • Table 9: Global Sales Forecast ($m) for Erbitux, 2013-2023
  • Table 10: Average Body Weight and Surface Area Across the 8MM
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Back to Top